cytochrome c oxidase subunit 6C pseudogene 5Genealiases: []
Q-omics provides the consensus-scored COX6CP5 profile across patient tissues and cancer cell-line models. COX6CP5 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, COX6CP5 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, COX6CP5 RNA expression shows 6,269 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight READ, BRCA, and STAD as cancer lineages where COX6CP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX6CP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX6CP5 survival associations across molecular data types. COX6CP5 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX6CP5 RNA expression–survival associations across cancer types. High COX6CP5 expression shows unfavorable associations in READ, UVM, KICH, LIHC, BRCA and HNSC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for COX6CP5 RNA expression.
This table summarizes COX6CP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for COX6CP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX6CP5 shows lower tumor expression in BRCA. The BRCA box plot shows higher COX6CP5 RNA expression in normal versus tumor tissue (log2 FC = −0.040, t-test p = .015).
This table shows molecular features associated with COX6CP5 in patient tissues and cancer cell lines. In patient samples, COX6CP5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
